Shares of Aarti Drugs Ltd gained nearly 2% on Monday to trade at ₹532 after the company reported robust earnings for the quarter ended June 2025.
The pharmaceutical company’s net profit surged 62.7% year-on-year to ₹54 crore in Q1 FY26, compared to ₹33.2 crore in the same quarter last year, driven by improved operational efficiency and better margins.
Revenue for the quarter rose 6.3% YoY to ₹590 crore, up from ₹555 crore last year, supported by healthy demand across segments. EBITDA came in at ₹74 crore, marking a 14% increase over ₹65 crore in the year-ago period.
Operating margins improved to 12.6% in Q1 FY26, compared to 11.7% last year, reflecting effective cost management and a favourable product mix.
The stock opened higher and gained as much as 1.7% over its previous close of ₹523.20, buoyed by the company’s strong quarterly performance.
